Myeloproliferative Neoplasms (MPN) and COVID-19
Completed
Conditions studied: Myeloproliferative Neoplasm, COVID
In brief
An increased risk of both venous and arterial thromboembolism was noted in reports from SARS-CoV-2-infected patients in China and has been confirmed in autopsy findings from patients who experienced sudden death. Myeloproliferative Neoplasms (MPNs), which encompass polycythemia vera, essential thrombocythemia and primary myelofibrosis, are thrombophilic disorders with a natural propensity to thrombosis that is fuelled by the intrinsic activation of inflammatory cytokines. It therefore follows that an underlying diagnosis of MPN may increase the risk of worse clinical outcomes and death during periods of active Covid-19 disease. This ambispective, observational study aims to elucidate the key factors which affect the clinical course of patients with MPN who develop Covid-19 disease.
Key facts
- Study ID
- NCT04385160
- Run by
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- People needed
- 552
- Starts
- 2020-05-13
- Expected to finish
- 2022-08-31
- Last updated by the study team
- 2025-09-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age > 18 years
- Confirmed diagnosed of MPN according to WHO criteria
- Diagnosis of COVID-19 based by the positivity of oropharyngeal swab performed between 15 February 2020 up to 15 February 2022
- Signed informed consent
You may not qualify if…
- None
Where it is running
- New York-Presbyterian/Weill Cornell Medical Center — New York, New York, United States
- National Specialised Hospital for Active Treatment of Hematological Diseases — Sofia, Bulgaria
- University hospital Dubrava-School of Medicine University of Zagreb — Zagreb, Croatia
- Hopital Saint-Louis — Paris, France
- University Hospital Halle, Department of Hematology/Oncology — Halle, Saale, Germany
- University Medical Center RWTH — Aachen, Germany
- University Medicine Greifswald - Hematology, Oncology, Stem Cell Transplantation and Palliative Care — Greifswald, Germany
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center — Minden, Germany
- Ospedale San Gerardo di Monza — Monza, Monza Brianza, Italy
- A.S.O. SS. Antonio e Biagio e C.Arrigo di Alessandria — Alessandria, Italy
- ASST-Papa Giovanni XXIII — Bergamo, Italy
- Policlinico S.Orsola-Malpighi — Bologna, Italy
- ASST-Spedali Civili — Brescia, Italy
- AOU Ospedale Careggi — Florence, Italy
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico — Milan, Italy
- IRCCS Ospedale San Raffaele — Milan, Italy
- Azienda Ospedaliero Universitaria Maggiore della Carità — Novara, Italy
- IRCCS Policlinico San Matteo — Pavia, Italy
- Policlinico Universitario Fondazione Agostino Gemelli — Roma, Italy
- A.O.U. Città della Salute e della Scienza di Torino — Torino, Italy
- Ospedale Policlinico "G.B. Rossi" Borgo Roma — Verona, Italy
- Ospedale San Bortolo — Vicenza, Italy
- Sobas Wroclaw Medical University · — Wroclaw, Poland
- Hospital Clínic De Barcelona — Barcelona, Barcellona, Spain
- Hospital del Mar — Barcelona, Barcellona, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.